Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited pupicidal activity against pupae of <i>A</i>. <i>albopictus</i> at 24 and 48h post treatment. by Perumal Vivekanandhan (4863484)

Subjects:

S1 Data - by Perumal Vivekanandhan (4863484)

Subjects:

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited adulticidal activity against adult of <i>A</i>. <i>albopictus</i> at 24 and 48h post treatment. by Perumal Vivekanandhan (4863484)

Subjects:

Quality of life years after randomization into the <i>Chuna</i> manual therapy and usual care groups. by Jae-Heung Cho (798319)

Subjects:

The response of the <i>A</i>. <i>albopictus</i> larval Glutathione S-transferase (GST) enzyme increased 7.8-fold in response to <i>M</i>. <i>robertsii</i>-derived copper nanopartic... by Perumal Vivekanandhan (4863484)

Subjects:

Changes in outcomes over time. by Jae-Heung Cho (798319)

Subjects:

Baseline characteristics of participants by randomized group. by Jae-Heung Cho (798319)

Subjects:

Schematic diagram of entomopathogen derived copper nanoparticles (CuNPs) and their toxic effects on target and non-target species. by Perumal Vivekanandhan (4863484)

Subjects:

Results of cost-effectiveness analysis of <i>Chuna</i> manual therapy compared with usual care^a. by Jae-Heung Cho (798319)

Subjects:

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited larvicidal activity against larvae of <i>A</i>. <i>albopictu</i> at 24 and 48h post treatment. by Perumal Vivekanandhan (4863484)

Subjects:

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited minimal toxicity effects against <i>E</i>. <i>eugeniae</i> at 24 and 48h post treatment. by Perumal Vivekanandhan (4863484)

Subjects:

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited minimal toxicity effects against <i>A</i>. <i>salina</i> at 24 and 48h post treatment. by Perumal Vivekanandhan (4863484)

Subjects:

Study timetable. by Jae-Heung Cho (798319)

Subjects:

Cumulative incidence curves of recovery by group. by Jae-Heung Cho (798319)

Subjects:

Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”

Comparison of 1^st, 2^nd, and 3^rd antibiotic prescription. by Thomas Hanslmeier (19949694)

Subjects: “…fluoroquinolone shares decreased…”